Pfizer Recognized as “2024 Corporate Partner of the Year” by American Cancer Society
For more than 20 years, Pfizer has been working to advance breakthroughs in cancer treatment and has pioneered several innovations across multiple types of cancer. But we know our efforts must go beyond the science. Many communities face significant barriers to accessing cancer screening and quality care, and no single organization alone can tackle these challenges. That’s why we partner with patient advocates across the oncology community with the goal of ensuring a more equitable future for cancer care.
In recognition of our efforts, we’re proud that Pfizer has been named by the American Cancer Society (ACS) as its 2024 Corporate Partner of the Year.
“Breakthrough medicines can’t save lives if they can’t reach the patients who need them – and through our longstanding partnerships with the American Cancer Society, we are working to address barriers to screening and treatment so that everyone impacted by cancer can receive the care they deserve,” said Tina Deignan, Commercial President, Pfizer Oncology. “We’re incredibly proud to be recognized by the American Cancer Society for our efforts and look forward to our ongoing collaboration.”
“It’s my honor to present this year’s Corporate Partner of the Year Award to Pfizer,” said Dr. Arif Kamal, Chief Patient Officer, American Cancer Society. “Pfizer’s support for the Change the Odds initiative reflects their strong commitment to transforming cancer care and has enabled ACS to further amplify critical programs and resources that are working to drive change in underserved communities across the country.”
The award reflects Pfizer and ACS’s joint efforts over a number of years on initiatives and programs that reflect the organizations’ shared priorities, including:
- In February 2024, Pfizer and ACS announced the launch of Change the Odds: Uniting to Improve Cancer Outcomes™, a three-year ACS initiative sponsored by Pfizer that aims to address cancer disparities and improve health outcomes in underrepresented communities across the United States through increasing access to and awareness of cancer screening, clinical trial opportunities and patient support and navigation.
- Since 2019, ACS has participated in the Pfizer Oncology Patient Centricity Ecosystem (POPCE), a group of advocacy and professional organizations that come together to share insights, identify concrete actions and collectively move forward on solutions to problems that inadvertently create barriers for cancer patients.
- Pfizer has supported ACS initiatives to improve equity in cancer care in the U.S. and globally through funding provided by our Global Medical Grant program and the Pfizer Foundation. These grants included support for ACS’s Hope Lodges, which offer patients and caregivers a free place to stay while undergoing cancer treatment.
- Pfizer has served as a long-time member and sponsor of several ACS Roundtables, including the Breast, Cervical, Lung and Prostate Cancer Roundtables. ACS Roundtables are national coalitions of organizations dedicated to a shared vision of giving all people a fair and just opportunity to prevent and survive cancer.
- Pfizer has supported ACS’s initiative focused on raising awareness of and increasing access to biomarker testing in the United States.
- Pfizer was a founding sponsor of the ACS Get Screened program, which worked to increase cancer screening rates following the COVID-19 pandemic, and our executive leadership served on ACS’s National Screening Consortium.
“With 1 in 3 people facing a cancer diagnosis in their lifetime, it is critical that we continue to work to ensure more equitable access to screenings, timely diagnosis and care – particularly in communities that are disproportionately impacted by cancer, but continue to be underserved,” said Angela Riemer, Vice President, VP & Head, US Business Policy & Public Affairs, Pfizer. “Our work with American Cancer Society is critical to advancing our shared mission and is making a real impact in these communities, and we look forward to many more years of collaboration.”
02.14.2025
02.13.2025
02.13.2025
02.11.2025
02.07.2025